Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

NCT00546871 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency Diseases (PID)

Interventions

DRUG: Immune Globulin Intravenous (Human), 10%

Sponsor

Baxalta now part of Shire